Drug Profile


Alternative Names: CRTX 080; Lixar; VPA 985; WAY VPA 985

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Chiesi USA; Palladio Biosciences
  • Class Azepines; Benzamides; Small molecules
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polycystic kidney disease
  • No development reported Hyponatraemia

Most Recent Events

  • 04 Oct 2017 Phase-II clinical trials in Polycystic kidney disease in USA (PO), prior to October 2017
  • 04 Oct 2017 Lixivaptan receives Orphan Drug status for Polycystic kidney disease in USA
  • 23 May 2017 Lixivaptan licensed to Palladio Biosciences worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top